Avidity Biosciences Announces New Positive AOC 1001 Data Dem

Avidity Biosciences Announces New Positive AOC 1001 Data Demonstrating Improvement in Multiple Additional Functional Endpoints and Favorable Long-term Safety and Tolerability in People with Myotonic Dystrophy Type 1

New AOC 1001 data demonstrate improvement in additional functional measures including hand grip, muscle strength and patient reported outcomes, augmenting previously reported positive data showing...

Related Keywords

South Carolina , United States , Charleston , San Diego , California , Nicholase Johnson , Navjot Rai , Sarah Boyce , Geoffrey Grande , Twitter , European Medicines Agency , World Muscle Society , Department Of Neurology At Virginia Commonwealth University , Linkedin , Avidity Biosciences Inc , Drug Administration , Exchange Commission , Prnewswire Avidity Biosciences Inc , Nasdaq , Antibody Oligonucleotide Conjugates , Annual Congress , Virginia Commonwealth University , Quantitative Muscle Testing , Muscle Testing , Orphan Designation , Myotonic Dystrophy Type , Oligonucleotide Conjugates , Annual Report , Private Securities Litigation Reform Act , Markets ,